Loading
A phase 3 trial of Datopotamab deruxtecan, Osimertinib, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer. ClinicalTrials.gov record last updated 2026-05-14: recruiting. Enrollment is planned at 744 participants. Primary completion is estimated at 2026-09-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Dato-DXd, Osimertinib, Pemetrexed, Carboplatin, Cisplatin. Registered primary measures: Progression free Survival (PFS).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Osimertinib, Pemetrexed, AstraZeneca, Cisplatin.
Shares Osimertinib, Pemetrexed, EGFR-mutated non-small-cell lung cancer, AstraZeneca.
Shares Datopotamab deruxtecan, TROP2, Osimertinib, AstraZeneca.
Shares Osimertinib, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, AstraZeneca, Small-cell lung cancer.
Shares Datopotamab deruxtecan, TROP2, Pemetrexed, AstraZeneca.
Shares Osimertinib, Pemetrexed, AstraZeneca, Cisplatin.
Shares Osimertinib, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/